FDA Approves HIV Drug from Pfizer and GlaxoSmithKline Joint Venture (PFE, GSK)
The FDA approved 50-milligram tablets of the drug Tivicay. Tivicay, when combined with other medications, is supposed to help the treatment of HIV-1 in adults and some children.
ViiV Healthcare submitted data to regulators data from four late-stage clinical studies that treated 2,557 adults and some data from tests on children 12 and older.
ViiV Healthcare was created in 2009 by the British-based GlaxoSmithKline and New York-based Pfizer to specialize in HIV treatments.
Pfizer shares were up 10 cents, or 0.34%, during pre-market trading on Tuesday, while GlaxoSmithKline shares were up 38 cents, or 0.74%.
The Bottom Line
Shares of Pfizer (PFE) offer a dividend yield of 3.29% based on last night’s closing price of $29.19 and the company’s annualized dividend payout of 96 cents per share.
Shares of GlaxoSmithKline (GSK) offer a dividend yield of 4.31% based on last night’s closing price of $51.30 and the company’s annualized dividend payout of $2.21 per share.
Pfizer (PFE) is recommended at this time, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. GlaxoSmithKline plc (GSK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Get FREE Dividend Tips, Updates & MoreWe respect your privacy
- Powerful dividend insights sent every weekday morning
- Gain instant access to actionable investing tips
- Strategically grow your portfolio’s profitability